Using G-CSF with Chemotherapy for Ovarian Cancer
Author Information
Author(s): A. Di Leo, E. Bajetta, F. Nole, L. Biganzoli, L. Ferrari, S. Oriana, G. Riboldi, S. Bohm, G. Spatti, F. Raspagliesi, E. Di Re, R. Fontanelli, A. Taiana, P. Zanon, F. Zunino, F. Di Re
Primary Institution: Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
Hypothesis
Does intramuscular administration of granulocyte colony-stimulating factor (G-CSF) improve the activity and tolerability of chemotherapy in ovarian cancer patients?
Conclusion
Intramuscular G-CSF is well tolerated and may effectively stimulate neutropoiesis in ovarian cancer patients undergoing chemotherapy.
Supporting Evidence
- Patients showed a significant reduction in absolute neutrophil count after G-CSF withdrawal.
- All patients completed at least one cycle of treatment.
- Seven of the 19 patients had measurable disease and objective responses were observed.
Takeaway
This study tested a new way to give a medicine that helps boost white blood cells in women with ovarian cancer who are getting chemotherapy. It seems to work well and is easy for patients.
Methodology
Nineteen patients with advanced ovarian cancer received a specific chemotherapy regimen along with G-CSF administered intramuscularly, and their neutrophil counts were monitored.
Potential Biases
Potential selection bias as all patients were from a single center and had specific eligibility criteria.
Limitations
The study lacks a control group and is based on a small sample size.
Participant Demographics
All participants were women aged between 18 and 60 with advanced ovarian cancer.
Statistical Information
P-Value
0.0001
Statistical Significance
p=0.0001
Want to read the original?
Access the complete publication on the publisher's website